Updates

CentralNic

October 2021

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

CentralNic’s H1 to end June show revenue increased by 57% to US$174.7m. Like-for-like organic growth increased from 9% in 2020 to 16% in Q1 2021 and 25% in Q2 2021. Adjusted EBITDA increased by 36% to US$20.5m.‘Marketing’ is the new name for the Monetisation division, which was formed following the acquisitions of Team Internet and Codewise and was the fastest growing segment, with revenues increasing by US$47.9m (or 99%) to US$96.4m. Organically it’s up 28% versus 10-12% organic growth seen elsewhere as it starts its journey to cross-sell a full suite of online marketing and monetisation solutions (including data analytics) to its SMB and corporate customer base. Zeus stops just short of upgrading, le ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

SThree - Massive upgrade to eps

Ergomed

CentralNIC (May 2023)

CentralNic (January 2023)

CentralNic (October 2022)

CentralNic (March 2022)

CentralNIC (February 2022)

CentralNic - Year-to-date organic growth now reaching a record 29%; 268p broker target (November 2021)

CentralNic (July 2021)

CentralNic (February 2021)

CentralNIC (January 2021)

CentralNIC - 20% eps accretive acquisition of Codewise (October 2020)

CentralNic (April 2020)

CentralNic (February 2020)

CentralNic - 44% eps accretive deal (December 2019)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X